Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants
In this study, we developed a recombinant MeV expressing the full-length SARS-CoV-2 spike protein (rMeV-S) and tested its efficacy using mouse and hamster models. In hCD46Tg mice, two-dose rMeV-S vaccination induced higher Th1 secretion and humoral responses than one-dose vaccination. Interestingly, neutralizing antibodies induced by one-dose and two-dose rMeV-S immunization effectively blocked the entry of the α, β, γ, and δ variants of SARS-CoV-2. Furthermore, two-dose rMeV-S immunization provided complete protection against SARS-CoV-2 in the hamster model. These results suggest the potential of rMeV-S as a vaccine candidate for targeting SARS-CoV-2 and its variants.PMID:36792434 | DOI:10.1016/j.vaccine.2023.02.005
Source: Vaccine - Category: Allergy & Immunology Authors: Hye Won Kwak Hyo-Jung Park Seo-Yeon Jung Eun Young Oh Sang-In Park Yeonhwa Kim Hyeong-Jun Park Sohyun Park You-Jin Kim Hae Li Ko Jung-Ah Lee Hyeran Won Yun-Ho Hwang Seo Yeon Kim Se Eun Kim Seoung Eun Bae Minhyuk Yoon Jae-Ouk Kim Manki Song Su Jeen Lee Ki- Source Type: research
More News: Allergy & Immunology | Child Development | Children | Coronavirus | Covid Vaccine | COVID-19 | Measles | Measles Vaccine | Respiratory Medicine | SARS | Study | Vaccines